Global LED phototherapy company Aesthetic Technology Ltd (ATL) has become Omni Partners LLP (Omni)’s third private equity investment in six months.
Omni Partners LLP (Omni), the lower mid-market focused investment manager, has announced the acquisition of Aesthetic Technology Ltd (ATL), the manufacturer of the award-winning Dermalux LED systems.
It is hoped that the acquisition and investment from Omni will accelerate ATL’s international expansion and product development into further medical treatment pathways.
Both Omni’s founder, Steven Clark, and the head of private equity, Charles Gallagher-Powell, who has prior experience working with the aesthetic technology company Lumenis, will join the ATL board of directors.
Founded in 2012, ATL is a multi-award-winning LED phototherapy company specialising in the development of energy-based devices for the medical, aesthetic and cosmetic markets.
Dermalux LED systems were voted ‘Treatment of The Year’ for five consecutive years at the UK Aesthetic Awards. Through the optimisation of three clinically proven combined wavelengths, the technology delivers medically CE-certified treatment for acne, wound healing and pain relief. It is also the only LED system in the world to hold medical approval for psoriasis.
“Being acquired by Omni is a very proud day for me and everyone at ATL, and recognition of everything we have achieved since we launched Dermalux just over ten years ago,” explained the co-founder of Aesthetic Technology Ltd., Louise Taylor. “Omni has a fantastic track record, and that coupled with their investment will accelerate our growth, with exciting developments being announced over the next couple of months. Omni definitely shares our vision for the company and our goal to build on the success we have enjoyed to date. Having celebrated ATL’s tenth anniversary just last month, I can’t wait to see what the next ten years will bring”.
Omni Partners LLP was established by Steven Clark in 2004 and operates as an FCA-regulated investment manager, managing the capital of global institutional investors across a variety of strategies. The acquisition of ATL demonstrates Omni’s commitment to backing founders and management teams, operating across tech-enabled services, healthcare, education and human capital.
“Aesthetic Technologies Ltd has been at the forefront of medical device technologies in the UK since 2012,” commented the head of private equity at Omni, Charles Gallagher-Powell. “We are proud to support the growth of this pioneering British business creating proprietary, ground-breaking products that signify quality, efficacy and safety. With significant tailwinds across the broader medical technology market, we look forward to working closely with ATL’s management and supporting their global expansion.”
Throughout the process, Omni was advised by RSM UK Group LLP (Financial & Tax), Candesic Limited (Commercial), Mayer Brown LLP (Legal) and Gallagher UK (Insurance). ATL was advised by KPMG and Brabners LLP. The transaction was not subject to regulatory approvals.
